Stoke Income Before Tax vs Ebitda Analysis

STOK Stock

USD 11.43 0.16 1.42%

Stoke Therapeutics financial indicator trend analysis is much more than just breaking down Stoke Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Stoke Therapeutics is a good investment. Please check the relationship between Stoke Therapeutics Income Before Tax and its Ebitda accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

Income Before Tax vs Ebitda

Income Before Tax vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Stoke Therapeutics Income Before Tax account and Ebitda. At this time, the significance of the direction appears to have totally related.

The correlation between Stoke Therapeutics' Income Before Tax and Ebitda is 1.0. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Ebitda in the same time period over historical financial statements of Stoke Therapeutics, assuming nothing else is changed. The correlation between historical values of Stoke Therapeutics' Income Before Tax and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Stoke Therapeutics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Income Before Tax i.e., Stoke Therapeutics' Income Before Tax and Ebitda go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Stoke Therapeutics income statement and is an important metric when analyzing Stoke Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Ebitda

Most indicators from Stoke Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Stoke Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.Issuance Of Capital Stock is expected to rise to about 67.4 M this year, although the value of Selling General Administrative will most likely fall to about 23.8 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	974K	1.5M	2.5M	2.6M
Total Operating Expenses	86.1M	116.8M	123.6M	68.1M

Reconciled Depreciation Total Operating Expenses

Stoke Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital
Total Assets		0.77	0.72	0.99	0.56	0.99	0.79	-0.94	-0.74	0.84	0.95	0.79	0.81	0.31	1.0	0.89	0.57	0.95	0.85	0.95	0.64	0.99	0.69	1.0	0.67	1.0
Other Current Liab	0.77		0.92	0.68	0.69	0.71	0.94	-0.57	-0.84	0.75	0.57	0.94	0.91	0.5	0.74	0.9	0.72	0.88	0.95	0.88	0.79	0.68	0.78	0.76	0.84	0.72
Total Current Liabilities	0.72	0.92		0.59	0.85	0.65	0.98	-0.52	-0.91	0.63	0.52	0.97	0.93	0.22	0.68	0.91	0.87	0.88	0.98	0.88	0.91	0.59	0.85	0.7	0.84	0.66
Total Stockholder Equity	0.99	0.68	0.59		0.44	0.99	0.68	-0.96	-0.64	0.84	0.97	0.69	0.72	0.33	0.99	0.82	0.44	0.89	0.75	0.89	0.52	1.0	0.6	0.99	0.58	1.0
Other Liab	0.56	0.69	0.85	0.44		0.49	0.81	-0.45	-0.95	0.45	0.41	0.81	0.77	-0.07	0.53	0.75	1.0	0.7	0.81	0.73	0.99	0.44	0.94	0.55	0.87	0.5
Net Tangible Assets	0.99	0.71	0.65	0.99	0.49		0.74	-0.97	-0.69	0.86	0.98	0.74	0.76	0.31	0.99	0.86	0.5	0.93	0.79	0.93	0.56	0.99	0.65	0.99	0.63	1.0
Property Plant And Equipment Net	0.79	0.94	0.98	0.68	0.81	0.74		-0.6	-0.92	0.76	0.61	1.0	0.98	0.37	0.76	0.94	0.83	0.93	0.99	0.93	0.87	0.68	0.87	0.78	0.89	0.73
Net Debt	-0.94	-0.57	-0.52	-0.96	-0.45	-0.97	-0.6		0.63	-0.79	-1.0	-0.6	-0.63	-0.16	-0.95	-0.77	-0.43	-0.84	-0.67	-0.85	-0.49	-0.96	-0.61	-0.95	-0.54	-0.96
Retained Earnings	-0.74	-0.84	-0.91	-0.64	-0.95	-0.69	-0.92	0.63		-0.69	-0.6	-0.92	-0.9	-0.18	-0.71	-0.89	-0.94	-0.86	-0.91	-0.88	-0.97	-0.64	-0.99	-0.72	-0.96	-0.69
Accounts Payable	0.84	0.75	0.63	0.84	0.45	0.86	0.76	-0.79	-0.69		0.79	0.76	0.83	0.64	0.84	0.87	0.43	0.85	0.75	0.85	0.52	0.84	0.68	0.84	0.75	0.84
Cash	0.95	0.57	0.52	0.97	0.41	0.98	0.61	-1.0	-0.6	0.79		0.61	0.64	0.18	0.96	0.77	0.4	0.85	0.68	0.85	0.47	0.97	0.57	0.95	0.51	0.96
Non Current Assets Total	0.79	0.94	0.97	0.69	0.81	0.74	1.0	-0.6	-0.92	0.76	0.61		0.99	0.37	0.76	0.94	0.83	0.93	0.99	0.93	0.87	0.69	0.87	0.78	0.89	0.74
Non Currrent Assets Other	0.81	0.91	0.93	0.72	0.77	0.76	0.98	-0.63	-0.9	0.83	0.64	0.99		0.45	0.78	0.95	0.78	0.93	0.96	0.93	0.83	0.72	0.86	0.79	0.89	0.76
Other Assets	0.31	0.5	0.22	0.33	-0.07	0.31	0.37	-0.16	-0.18	0.64	0.18	0.37	0.45		0.3	0.35	-0.07	0.32	0.3	0.31	0.03	0.33	0.18	0.3	0.39	0.3
Cash And Short Term Investments	1.0	0.74	0.68	0.99	0.53	0.99	0.76	-0.95	-0.71	0.84	0.96	0.76	0.78	0.3		0.87	0.54	0.93	0.82	0.94	0.6	0.99	0.66	1.0	0.64	1.0
Common Stock Shares Outstanding	0.89	0.9	0.91	0.82	0.75	0.86	0.94	-0.77	-0.89	0.87	0.77	0.94	0.95	0.35	0.87		0.75	0.97	0.96	0.97	0.81	0.82	0.85	0.88	0.85	0.85
Non Current Liabilities Total	0.57	0.72	0.87	0.44	1.0	0.5	0.83	-0.43	-0.94	0.43	0.4	0.83	0.78	-0.07	0.54	0.75		0.71	0.83	0.73	0.99	0.44	0.92	0.56	0.86	0.51
Capital Surpluse	0.95	0.88	0.88	0.89	0.7	0.93	0.93	-0.84	-0.86	0.85	0.85	0.93	0.93	0.32	0.93	0.97	0.71		0.96	1.0	0.77	0.89	0.8	0.94	0.79	0.92
Other Current Assets	0.85	0.95	0.98	0.75	0.81	0.79	0.99	-0.67	-0.91	0.75	0.68	0.99	0.96	0.3	0.82	0.96	0.83	0.96		0.96	0.87	0.75	0.86	0.83	0.86	0.8
Other Stockholder Equity	0.95	0.88	0.88	0.89	0.73	0.93	0.93	-0.85	-0.88	0.85	0.85	0.93	0.93	0.31	0.94	0.97	0.73	1.0	0.96		0.79	0.89	0.83	0.94	0.81	0.92
Total Liab	0.64	0.79	0.91	0.52	0.99	0.56	0.87	-0.49	-0.97	0.52	0.47	0.87	0.83	0.03	0.6	0.81	0.99	0.77	0.87	0.79		0.52	0.95	0.62	0.9	0.58
Net Invested Capital	0.99	0.68	0.59	1.0	0.44	0.99	0.68	-0.96	-0.64	0.84	0.97	0.69	0.72	0.33	0.99	0.82	0.44	0.89	0.75	0.89	0.52		0.6	0.99	0.58	1.0
Property Plant And Equipment Gross	0.69	0.78	0.85	0.6	0.94	0.65	0.87	-0.61	-0.99	0.68	0.57	0.87	0.86	0.18	0.66	0.85	0.92	0.8	0.86	0.83	0.95	0.6		0.68	0.97	0.64
Total Current Assets	1.0	0.76	0.7	0.99	0.55	0.99	0.78	-0.95	-0.72	0.84	0.95	0.78	0.79	0.3	1.0	0.88	0.56	0.94	0.83	0.94	0.62	0.99	0.68		0.65	1.0
Non Current Liabilities Other	0.67	0.84	0.84	0.58	0.87	0.63	0.89	-0.54	-0.96	0.75	0.51	0.89	0.89	0.39	0.64	0.85	0.86	0.79	0.86	0.81	0.9	0.58	0.97	0.65		0.62
Net Working Capital	1.0	0.72	0.66	1.0	0.5	1.0	0.73	-0.96	-0.69	0.84	0.96	0.74	0.76	0.3	1.0	0.85	0.51	0.92	0.8	0.92	0.58	1.0	0.64	1.0	0.62

Click cells to compare fundamentals

Stoke Therapeutics Account Relationship Matchups

Stoke Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	228.8M	297.9M	238.9M	256.1M	228.3M	213.7M
Other Current Liab	3.4M	8.9M	13.2M	13.4M	11.8M	8.7M
Total Current Liabilities	4.1M	11.4M	17.1M	31.4M	30.8M	15.9M
Total Stockholder Equity	224.4M	286.1M	217.8M	184.8M	159.6M	184.9M
Other Liab	221K	342K	3.9M	37.1M	42.7M	44.8M
Net Tangible Assets	224.4M	286.1M	217.8M	184.8M	212.6M	186.4M
Property Plant And Equipment Net	2.5M	3.8M	9.1M	11.4M	12.4M	6.4M
Net Debt	(222.5M)	(287.2M)	(143.4M)	(111.2M)	(189.4M)	(198.8M)
Retained Earnings	(58.0M)	(110.3M)	(196.1M)	(297.2M)	(401.8M)	(381.8M)
Accounts Payable	751K	1.5M	2.4M	766K	1.7M	1.3M
Cash	222.5M	287.3M	144.9M	113.6M	191.4M	167.7M
Non Current Assets Total	2.7M	4.0M	9.6M	12.0M	13.0M	6.8M
Other Assets	205K	1.3M	248.5M	569K	654.4K	621.6K
Cash And Short Term Investments	222.5M	287.3M	219.8M	229.6M	201.4M	199.2M
Common Stock Shares Outstanding	18.0M	33.5M	36.7M	38.9M	44.0M	32.6M
Liabilities And Stockholders Equity	228.8M	297.9M	238.9M	256.1M	228.3M	213.7M
Non Current Liabilities Total	221K	422K	3.9M	39.8M	38.0M	39.9M
Capital Surpluse	282.5M	396.4M	414.0M	483.2M	555.6M	315.1M
Other Current Assets	3.3M	6.6M	9.3M	13.9M	13.9M	7.5M
Other Stockholder Equity	282.5M	396.4M	414.0M	483.2M	561.4M	358.4M
Total Liab	4.3M	11.8M	21.1M	71.2M	68.8M	72.2M
Net Invested Capital	224.4M	286.1M	217.8M	184.8M	159.6M	184.9M
Property Plant And Equipment Gross	2.5M	3.8M	9.1M	11.4M	19.1M	20.1M
Total Current Assets	226.0M	293.9M	229.2M	244.1M	215.3M	206.9M
Non Current Liabilities Other	221K	422K	3.9M	3.0M	4.9M	5.1M
Net Working Capital	221.9M	282.5M	212.1M	212.7M	184.5M	191.0M
Property Plant Equipment	2.5M	2.7M	9.1M	6.7M	7.7M	4.1M
Net Receivables	281K	6K	132K	588K	64K	60.8K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Stoke Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stoke Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stoke Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Stoke Therapeutics Stock:

How To Invest In Stoke

Details

Is Stoke Stock a good investment?

Details

What is Stoke Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.08)

Revenue Per Share

0.328

Quarterly Revenue Growth

0.479

Return On Assets

(0.28)

Return On Equity

(0.52)

The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Stoke Income Before Tax vs Ebitda Analysis

Income Before Tax vs Ebitda

Income Before Tax vs Ebitda Correlation Analysis

Correlation Coefficient

Income Before Tax

Ebitda

Stoke Therapeutics fundamental ratios Correlations

Stoke Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Stoke Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Total Stockholder Equity
Non Current Liabilities Total	+ 1.0	Other Liab

Cash	- 1.0	Net Debt
Property Plant And Equipment Gross	- 0.99	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Net Debt	- 0.97	Net Tangible Assets
Non Current Liabilities Other	- 0.96	Retained Earnings
Net Working Capital	- 0.96	Net Debt